<DOC>
	<DOCNO>NCT01696474</DOCNO>
	<brief_summary>This multicenter , phase II , open label study enroll patient chronic cold agglutinin disorder . A single course Bortezomib give dose 1,3 mg/sqm iv day 1 , 4 , 8 , 11 .</brief_summary>
	<brief_title>Short Course Bortezomib Anemic Patients With Refractory Cold Agglutinin Disease</brief_title>
	<detailed_description>Based activity MM , single agent Bortezomib test phase II trial lymphoplasmacytic lymphoma , disorder frequently associate CAD , achieve 40-80 % response . These striking clinical response indicate proteasome activity critical survival immunoglobulin-secreting cell . The resolution transfusion requirement two patient refractory CAD associate IgMk monoclonal gammopathy report treatment short course Bortezomib . It may interest test efficacy Bortezomib large series patient refractory CAD , idiopathic associate otherwise asymptomatic B cell clonal disorder , evaluate duration clinical benefit .</detailed_description>
	<mesh_term>Anemia , Hemolytic , Autoimmune</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Cold agglutinin</mesh_term>
	<mesh_term>Agglutinins</mesh_term>
	<criteria>Patients chronic cold agglutinin disorder require hemoglobin concentration 10g/L determine least monthly two month enter trial ; Failure least one previous treatment attempt ; Hemoglobin level assessment ; Cold agglutinin ( CA ) titer 4Â°C 64 high ; Written inform consent . Presence concomitant lymphoproliferative disorder require specific treatment reason cold agglutinin relate hemolytic anemia ; Preexisting peripheral neuropathy ; Known hypersensitivity Bortezomib ; Noncooperative behaviour noncompliance ; Psychiatric diseases condition might impair ability give inform consent ; Patients pregnant ( woman childbearing potential must negative serum pregnancy test ) . Postmenopausal woman must amenorrhoic least 24 month consider nonchildbearing potential . Male female patient must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Refractory cold agglutinin disease</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>blood-transfusion</keyword>
</DOC>